Compare Ishares Msci Thailand Etf (THD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Thailand Etf vs Travere Therapeutics Inc. Common Stock — how do they compare? Ishares Msci Thailand Etf trades at $71.15 (market cap $424.09M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 11.5× Ishares Msci Thailand Etf's market cap, and Ishares Msci Thailand Etf is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Thailand Etf for 67 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| THD | TVTX | |
|---|---|---|
Market Cap | $424.09M | $4.88B |
Volume | 1,217,048 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $75.06 | $67.52 |
52-Week Low | $57.86 | $26.79 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
THD (iShares MSCI Thailand ETF) trades at $71.17, down 0.27% with bearish technical signals across moving averages and oscillators. Short interest surged 90.6% in September 2026 (Defense World, 2026-10-01), indicating rising bearish sentiment. The ETF has delivered strong 38% returns over the past year (Seeking Alpha, 2026-07-09) but faces headwinds from capital rotation away from Asian AI-related markets.
Outlook remains cautious given technical weakness and elevated short positioning. Investment opportunity exists for exposure to Thailand's AI hardware plays like Delta Electronics, but vulnerability to profit-taking and regional capital outflows presents significant near-term risks for shareholders.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
